跳至主要内容

Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development

 On June 24, 2024, Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research  (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo).  The two parties will engage in comprehensive and in-depth collaboration in multiple fields, including animal electrocardiogram diagnostics and personnel training, as well as animal ophthalmic disease diagnosis and model establishment, to jointly promote the development of innovative drugs.

Hetuo.webp

Complementary advantages drive improvement; working together to empower new capabilities
 Supporting the development of cardiovascular and ophthalmic disease drugs

Hetuo is a CRO specializing in preclinical pharmacodynamic evaluation, focusing on translational medicine platform technologies, and actively promoting the industrialization of medicine.  The company adheres to GLP standards, implementing scientific management of projects to ensure the authenticity, accuracy/scientific integrity, and consistency of research and development results.  Currently, Hetuo has successfully developed animal models covering cardiovascular, neurological, gastrointestinal, ophthalmic, dermatological, metabolic, and urinary system diseases. The company offers customized research services and has established three leading pharmacodynamic evaluation platforms, particularly in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs.

Medicilon, relying on two decades of extensive experience in the preclinical research field of biopharmaceutical, provides one-stop new drug R&D services that meet domestic and international regulatory standards, covering drug discovery, pharmaceutical research, and preclinical research. Medicilon's expertise spans cutting-edge areas such as bispecific/multispecific antibodies, antibody-drug conjugates (ADC), mRNA vaccines, small nucleic acid drugs, protein degradation targeting chimeras (PROTAC), and cell and gene therapy (CGT).  Currently, Medicilon has successfully assisted 480 IND applications in entering clinical trials approved by China's NMPA, the US FDA, the EU EMA, and Australia TGA.

This collaboration stems from both parties' deep insights into the trends in innovative drug development and their shared mission to empower the innovation process in pharmaceutical R&D.  After discussions and exchanges, both parties have signed a collaboration agreement on training and services for experimental animal electrocardiogram diagnostics. We believe that with deep collaboration and complementary strengths, we can provide clients with higher quality and more efficient R&D services for cardiovascular drugs and ophthalmic disease drugs, facilitating the early entry of innovative drugs into clinical trials for our clients.

It is worth mentioning that on the afternoon of June 23rd, Dr. Xiarong Sun, Project Director of Hetuo, participated as a keynote speaker at the General Training on Experimental Animal Electrocardiography Basics, Chinese Academy of Sciences held jointly by the Shanghai Experimental Animal Society and MPR. Dr. Sun shared his professional experience and skills and was highly praised by the attendees.  As the collaboration deepens between both parties, the Hetuo team will continue to provide progressive professional training for MPR, further enhancing industry expertise and service quality.

This collaboration represents a joint commitment from both sides to empower pharmaceutical innovation and reflects a steadfast confidence in the future of drug research and development innovation.  Medicilon will join hands with Hetuo to face challenges together, explore opportunities, and provide strong support in exploring new therapeutic areas and methods for clients!

About Hetuo

Hetuo Innovation, as a CRO service company specializing in preclinical efficacy evaluation of pharmaceutical products, provides pharmacology evaluation services to global pharmaceutical R&D companies and research institutes.  Hetuo adheres to GLP (Good Laboratory Practice) standards, ensuring the scientific management and implementation of projects to guarantee the authenticity, scientific validity, and consistency of research and development results.  Currently, Hetuo has developed animal models for cardiovascular, neurological, digestive, ophthalmic, dermatological, metabolic, and urological diseases. They offer customized animal model establishment and research services tailored to specific research needs.  Hetuo aims to provide scalable, standardized, highly regulated, and reliable services, shortening the drug and medical device development cycles for global clients, reducing development costs and risks. Upholding the company mission, Hetuo contributes to pharmaceutical R&D, paving the way for a healthier future.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文